This afternoon we watched Moderna rise 4.1% to a price of $35.12 per share. The Large-Cap Biotechnology company is now trading -37.85% below its average target price of $56.51. Analysts have set target prices ranging from $25.0 to $212.0 per share for Moderna, and have given the stock an average rating of hold.
The stock has an above average percentage of its shares sold short at 13.9%, and a short ratio of 3.29. The company's insiders own 9.6% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.8% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Vanguard Group Inc | 10% | 40,323,750 | $1,416,371,718 |
| 2024-12-31 | Baillie Gifford and Company | 10% | 38,889,571 | $1,365,996,181 |
| 2024-12-31 | Blackrock Inc. | 7% | 25,791,947 | $905,942,138 |
| 2024-12-31 | FMR, LLC | 5% | 18,664,634 | $655,595,269 |
| 2024-12-31 | State Street Corporation | 5% | 17,577,236 | $617,400,414 |
| 2024-12-31 | Theleme Partners LLP | 2% | 7,306,861 | $256,653,492 |
| 2024-12-31 | Geode Capital Management, LLC | 2% | 7,241,354 | $254,352,559 |
| 2024-12-31 | UBS Group AG | 1% | 5,073,371 | $178,202,156 |
| 2024-12-31 | Invesco Ltd. | 1% | 5,006,462 | $175,851,977 |
| 2024-12-31 | Flagship Pioneering Inc. | 1% | 4,632,149 | $162,704,233 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Moderna.
